Unit:
Τομέας ΧειρουργικήςLibrary of the School of Health Sciences
Author:
Korfias Dimitrios
Dissertation committee:
Ιωάννης Κόντης, Αν. Καθηγητής, Ιατρική, ΕΚΠΑ
Κωνσταντίνος Γεννατάς, Καθηγητής, Ιατρική, ΕΚΠΑ
Χρήστος Παπαδημητρίου, Καθηγητής, Ιατρική, ΕΚΠΑ
Δημήτριος Βλαχοδημητρόπουλος, Αν. Καθηγητής, Ιατρική, ΕΚΠΑ
Ιωάννης Παπακωνσταντίνου, Αν. Καθηγητής, Ιατρική, ΕΚΠΑ
Νικόλαος Γούτας, Αν. Καθηγητής, Ιατρική, ΕΚΠΑ
Ματρώνα Φράγκου-Πλεμμένου, Επίκ. Καθηγήτρια, Ιατρική, ΕΚΠΑ
Original Title:
Μελέτη της παρουσίας βλαστικών καρκινικών κυττάρων και άλλων προγνωστικών δεικτών σε καρκίνο του μαστού
Translated title:
The study of cancer stem cells expresion and other biomarkers in ductal breast cancer
Summary:
Aim of this study is to evaluate the immuno- expression of stem cell markers CD44, CD24, CD133, ALDH-1 in breast carcinomas and investigate any correlation with stage, degree of tumor differentiation, cell proliferation index and hormone receptors status.
Material -Method: 104 cases of invasive ductal breast carcinomas were studied, classified according to grade and stage, hormonal status and C-erb-2 expression. A semi-automatic Ventana method was used to examine by semi-quantitative method the immuno-expression of anti-CD133 antibodies (Abcam,), anti-mouse CD24 and CD44 (Biotech), anti-ALDH1 (Immunogen)
Results: CD44, CD24, ALDH1 markers presented a statistically significant relation with high disease stage and triple negative cancers (94%-55,5%).
CD133 correlated with triple negative cancers (55.55%). No correlation with other clinical data or tumor differentiation was observed.
Conclusion: Triple negative breast cancers express specific stem cell markers responsible for cell/stroma interaction and this is a useful tool in predicting tumor progression and developing specific targeted therapies.
Main subject category:
Health Sciences
Keywords:
Cancer stem cells, Breast cancer, Cancer specific biomarkers, CD44, CD24, CD133, ALDH1
Number of references:
177
